a n a ly s i s Recent studies indicate that a subclass of APOBEC cytidine deaminases, which convert cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction, may induce mutation clusters in human tumors. We show here that throughout cancer genomes APOBEC-mediated mutagenesis is pervasive and correlates with APOBEC mRNA levels. Mutation clusters in whole-genome and exome data sets conformed to the stringent criteria indicative of an APOBEC mutation pattern. Applying these criteria to 954,247 mutations in 2,680 exomes from 14 cancer types, mostly from The Cancer Genome Atlas (TCGA), showed a significant presence of the APOBEC mutation pattern in bladder, cervical, breast, head and neck, and lung cancers, reaching 68% of all mutations in some samples. Within breast cancer, the HER2-enriched subtype was clearly enriched for tumors with the APOBEC mutation pattern, suggesting that this type of mutagenesis is functionally linked with cancer development. The APOBEC mutation pattern also extended to cancer-associated genes, implying that ubiquitous APOBEC-mediated mutagenesis is carcinogenic.
Genome instability triggers the development of many types of cancers 1, 2 . Radiation and chemical damage are traditionally invoked as culprits in theories of carcinogenic mutagenesis 3 . However, normal enzymatic activities can also be a source of DNA damage and mutation. Cytidine deaminases, which convert cytosine bases to uracil, likely contribute to DNA damage 4 . Activation-induced cytidine deaminase (AID), a key enzyme in adaptive immunity, not only initiates the hypermutation and class-switch recombination of immunoglobulin genes but also can mutate chromosomal DNA at a limited number of secondary targets, some of which have been implicated in carcinogenesis 5 . In addition to AID, the human genome encodes several homologous APOBEC (apolipoprotein B mRNAediting enzyme, catalytic polypeptide-like) cytidine deaminases that function in innate immunity as well as in RNA editing 6 . Previous human cell culture studies showed that a subclass of APOBECs with mutational specificity for TC motifs (with the mutated base underlined) is capable of inducing mutations in chromosomal and mitochondrial DNA and therefore could have a role in carcinogenesis [7] [8] [9] .
(APOBEC without the gene-specifying suffix is used hereafter to designate a subclass of cytidine deaminases with TC motif specificity. Note that, on the basis of motif specificity, APOBEC3G and AID do not fall into this subclass.) Supporting a role for APOBECs in cancer, a mutation signature consistent with APOBEC editing was found in individual cancer-related genes 10, 11 . Recently, clustered mutations (termed kataegis in ref. 12 ) identified through next-generation sequencing suggested that APOBECs can induce base substitutions in tumor genomes 12, 13 . Clustered mutations showed even higher preference for a more stringent TCW motif (where W corresponds to either A or T). Tightly linked strand-coordinated clustered mutations (clusters whose mutations all occur at one type of nucleotide) were often colocalized with rearrangement breakpoints, suggesting that this mutagenesis results from aberrant DNA double-strand break (DSB) repair that produces single-stranded DNA (ssDNA), an ideal substrate for the APOBEC enzymes 6 . The frequency of base substitutions in the APOBEC motif was higher for clustered mutations identified in whole genome-sequenced breast cancers 12 , as well as in multiple myeloma, prostate, and head and neck cancers 13 . Notably, non-clustered substitutions in the TCW motif occurred near rearrangement breakpoints more frequently than expected by random chance across the genomes of several cancer types 14 . Analysis of breast cancer sequencing and expression data suggested that it is specifically APOBEC3B that causes mutations in this cancer type 9 .
Despite the indication that APOBEC-mediated mutagenesis may have a role in cancer, it was unclear how strong of a mutagenic factor APOBEC enzymes are, whether APOBEC mutagenesis is a ubiquitous characteristic of many cancer types and cases, and whether it is associated with any specific tumor characteristics. Here we have developed an analysis to evaluate the strength of the APOBEC mutation pattern in individual samples from multiple whole-genome and exome mutation data sets, such as TCGA. We found that the APOBEC mutation pattern is prominent and even prevailing in many samples An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers a n a ly s i s from several types of cancer, in contrast to other cancer types where it is barely detectable, and that it correlates with APOBEC mRNA levels and extends into a subset of genes considered by multiple criteria to be cancer drivers.
RESULTS

A pattern for detecting APOBEC mutagenesis
Our approach to the statistical exploration of complex mutation spectra in multiple cancer samples involved the formulation of a single hypothesis surrounding a diagnostic mutation pattern, which uses knowledge obtained in previous experiments as well as in data analyses and minimizes overlap with other known sequence-specific mutagenesis mechanisms. The first step in defining a measure for a pattern of APOBEC-mediated mutagenesis in a cancer sample was to find mutations that occurred in the motif most likely to be an APOBEC-specific target. We chose the TCW motif instead of the less stringent TC motif because of its demonstrated prevalence in mutagenesis caused by some APOBECs in model systems as well as in mutation clusters found in cancers (refs. 9,12,13 and references therein). The more stringent TCW motif also eliminated potential overlap with sequence-specific mutagenesis in highly mutable CpG sequences that would occasionally be preceded by a thymine. Second, we proposed that APOBEC-induced mutagenesis would involve primarily cytosine-to-guanine and/or cytosine-to-thymine substitutions, with rare cytosine-to-adenine changes. This substitution pattern is based on the tendency of translesion synthesis to misincorporate cytosine or adenine bases across from abasic sites (resulting in cytosine-to-guanine and cytosine-to-thymine mutations) that are generated frequently by the activity of uracil DNA glycosylase [15] [16] [17] toward the products of both spontaneous and APOBEC-induced cytosine deamination, as well as copying a cytosine deamination-derived uracil (resulting in cytosine-to-thymine changes). Thus, in the present analysis, we defined cytosine-to-thymine and cytosine-to-guanine substitutions in TCW motifs as APOBEC signature mutations. To identify samples that experienced APOBEC-mediated mutagenesis, we further defined an APOBEC mutagenesis pattern within a sample as a statistically significant enrichment of the frequency of APOBEC signature mutations compared to that expected with random mutagenesis (Online Methods). Enrichment for APOBEC signature mutations (TCW to TTW or TGW and the complementary WGA to WAA or WCA changes) among all similar mutations of cytosine or guanine bases (cytosine to thymine or guanine and guanine to adenine or cytosine) was calculated relative to the frequency of the APOBEC mutation motif (TCW or WGA) in the 41-nucleotide regions centered on the mutated bases. We used only the nucleotides immediately surrounding the mutations in this calculation because APOBEC enzymes are thought to scan a limited area of ssDNA to deaminate a cytosine in a preferred motif 18, 19 . This approach does not exclude any given area of the genome in general, but rather uses the areas within each sample where mutagenesis has happened, and then evaluates whether the mutagenesis in this sample was enriched for APOBEC signature mutations. To test the accuracy of our analysis, we compared our measure of the APOBEC mutation pattern (fold enrichment) to a previously reported measure of APOBEC-mediated mutagenesis obtained via a very different approach involving the mathematical decomposition and extraction of multiple mutation signatures from 21 breast cancer samples 12 . The results showed a very high level of correlation between the measures (Supplementary Fig. 1 and Supplementary Table 1) , supporting the applicability of our method. Moreover, our analysis remained robust even when applied to samples containing small numbers of mutations. The fold enrichment of APOBEC-mediated mutations in a subset of mutations representing exomes from the aforementioned 21 breast cancers (~2% of total mutations in the whole genome) correlated strongly with values obtained from the entire genome (Supplementary Fig. 2) , suggesting that our analysis may be effectively applied to mutations identified through exome sequencing and would thereby substantially increase the number of cancer samples that are available for analysis.
An APOBEC mutagenesis pattern in mutation clusters
We evaluated the APOBEC mutation pattern in a large number of whole-genome and exome mutation data sets accumulated in TCGA as well as in several publications 20, 21 . APOBECs are highly specific for ssDNA and are capable of simultaneously making multiple mutations if an ssDNA region persists 17, 19 . Such mutations are strand coordinated, as changes in multiple cytosines occur on the same DNA strand. We and others have detected this APOBEC mutation pattern in cytosine and complementary guanine strand-coordinated clusters from a limited number of whole genome-sequenced tumors 12, 13 . These clusters often colocalize with rearrangement breakpoints 12, 13 ( Fig. 1a and Supplementary Fig. 3 ), which agrees with mutagenesis occurring in ssDNA regions that are either prone to breakage and/or are formed during a DSB repair process. Clustered cytosine or guanine mutations identified previously 13 as well as in additional analysis of whole genome-sequenced colorectal adenocarcinomas 22 presented here showed a strong APOBEC mutation pattern (with the highest enrichment observed for the TCW motif and strong preference for cytosine-to-thymine and cytosine-to-guanine changes in this motif; Table 2) .
We next addressed whether an APOBEC mutation pattern is common among different cancer samples and types. We accumulated lists of cancer-specific mutations from the whole-exome sequencing of 2,680 tumors, mostly by the TCGA Research Network (Supplementary Table 3 ). Although exome sequencing substantially increases the number of samples available for analysis, its general specificity for protein-coding regions results in only ~1% of total genomic DNA being assessed. In identifying clusters from exome sequencing, we therefore estimated the total mutation load in a given tumor sample under the assumption that exome mutations constitute 1% of mutations in the entire genome, using this value to identify clusters with our previously described algorithm 13 . This method found 498 total clusters in the 2,680 sequenced exomes from 14 different cancer types. In total, 218 cytosine-or guanine-coordinated clusters were identified, occurring in every cancer type analyzed except acute myeloid leukemia (LAML) ( Supplementary Fig. 4 ). Similar to results obtained by whole-genome analysis (compare Figs. 1a and 1b), these clusters showed a robust APOBEC mutation pattern, whereas other known mutagenic motifs involving cytosine or guanine nucleotides were depleted. In contrast, the APOBEC mutation pattern was barely detectable or was undetectable in non-coordinated clustered cytosine and guanine mutations and scattered mutations, respectively ( Supplementary Fig. 5 ). The enrichment of APOBEC signature mutations in cytosine-or guanine-coordinated clusters was more pronounced in clusters with >2 mutations (Supplementary Fig. 4 ) because clusters with only 2 mutations had a higher chance of occurring independently through non-APOBEC-dependent mechanisms.
The APOBEC mutagenesis pattern across 2,680 cancer exomes
The strength of the APOBEC mutation pattern in cytosine-or guanine-coordinated clusters from our analysis of exome mutations (Fig. 1b) was comparable to that of clusters found in whole-genome mutation lists (Fig. 1a) , suggesting that exome-wide mutation data npg a n a ly s i s may be sufficient to detect the APOBEC mutation pattern among all mutations in a sample's exome. Indeed, the APOBEC mutation pattern was clearly present throughout many exomes, indicating that APOBEC enzymes were probably a major source of mutagenesis in these samples ( Fig. 2a and Supplementary Table 4) . Samples showing the APOBEC mutation pattern occurred primarily in six cancer types, whereas the other eight cancer types were depleted of this pattern, despite high general mutation rates in many samples (P < 0.0001, two-sided χ 2 comparison of the number of samples in each cancer type showing fold enrichment of APOBEC signature mutations greater than the median fold enrichment for all samples; n = 2,680). Bladder (BLCA), cervical (CESC), head and neck (HNSC), breast (BRCA) and lung cancers (LUAD and LUSC) were enriched in samples with a high level of APOBEC mutagenesis or having greater odds ratios compared to those for the total range of APOBEC-mediated mutagenesis in exomes ( Fig. 2 and Supplementary Fig. 6a,b) . Motifspecific functional selection is unlikely to have caused the observed over-representation of the APOBEC mutation pattern, as corresponding calculations of fold enrichment for silent and noncoding mutations in each sample produced similar results (Supplementary Fig. 7) . Across all tumors analyzed, high fold enrichment of APOBEC mutations correlated strongly with decreased Fisher's q value as well as with an increase in the fraction of total mutations in a tumor that had the APOBEC signature (Supplementary Fig. 8 ). In individual tumors with a strong APOBEC pattern, the number of APOBEC signature mutations was often large, making the APOBEC enzyme the predominant source of mutations in the sample (Fig. 2b) . Notably, some samples contained over a thousand APOBEC signature mutations, constituting up to 68% of mutations in the exome.
In cancer types where an APOBEC mutation pattern was not noticeable in the exome data, the pattern was detectable in clusters of strandcoordinated cytosine (or guanine) mutations from whole-genome data. Whole-genome data contained about 100-fold more mutations than exome data, facilitating the detection of clusters. We previously reported such clusters to be enriched for the APOBEC mutation pattern when considering the mutations in whole genome-sequenced prostate carcinomas 13 , and we show here the same pattern in nine whole-genome colorectal cancer mutation data sets 22 ( Supplementary  Fig. 3 ). In each of these data sets, many of the cytosine-or guaninecoordinated clusters colocalized with chromosomal rearrangement breakpoints, a phenomenon that supports the involvement of ssDNA (the exclusive substrate of APOBEC enzymes) in cluster formation 23, 24 . Neither cancer type, however, showed a detectable presence of the APOBEC mutation pattern in exome data. Thus, the APOBEC mutagenesis pattern seems to be ubiquitous at a background level in all types of cancer but is more prominent in particular types.
APOBEC-mediated mutagenesis correlates with APOBEC mRNA
Several cancer type-specific factors, including the availability of ssDNA substrate and the expression level of APOBEC enzymes, could contribute to the extent of APOBEC-mediated mutagenesis. Recently, a tumor-specific increase in the transcription of APOBEC3B, determined by quantitative PCR (qPCR) and microarray analysis, as well as by RNA sequencing (RNA-seq), in breast cancer samples was shown to correlate with an increased number of cytosine-to-thymine transitions 9 . Cytosine-to-thymine mutations are a relaxed measure of total deamination, which includes both the APOBEC signature in TCW defined in our analysis as well as mutations stemming from other processes. We used RNA-seq expression data to address whether the expression of any of the eight APOBEC enzymes known to have biochemical deamination activity toward DNA correlated with the observed extent of APOBEC-mediated mutagenesis. Consistent with the previous report in breast cancer, APOBEC3B expression was frequently higher in tumor samples compared to matched normal samples; however, median expression of APOBEC3H and APOBEC3A (Supplementary Figs. 9 and 10) was also higher by approximately twofold in tumors. Of the 483 breast cancers analyzed for both APOBEC-mediated mutagenesis and APOBEC expression, APOBEC3B as well as APOBEC3A mRNA levels correlated strongly with the total number of cytosine-to-thymine mutations per exome (Supplementary Fig. 11a ; Spearman's r = 0.233, Bonferronicorrected q < 0.001 and Spearman's r = 0.1998, Bonferroni-corrected q < 0.001, respectively). Notably, when transcript levels were compared to the number of mutations conforming to our stringent definition of APOBEC-mediated mutagenesis (TCW to TTW or TGW), the strength of the association was higher for both enzymes ( Fig. 3a; Spearman's r = 0.3150, Bonferroni-corrected q < 0.001 and Figure 1 APOBEC mutation pattern in clusters. (a,b) Analysis of all clusters identified in whole-genome data sets, including 23 multiple myeloma 47 , 2 head and neck squamous cell carcinoma 21 , 7 prostate carcinoma 48 and 9 colorectal adenocarcinoma 22 data sets (a), and in 2,680 exomes from 14 different cancer types from TCGA as well as from other published sources 20, 21 (Online Methods) (b). Top, colocalization of clusters with breakpoints was identified as described in ref. 13 . Clusters identified as being close to breakpoints had at least one mutation within 20 kb of a breakpoint. N, any nucleotide. Middle, fold enrichment (shown above bars) of mutation motifs (with the mutated base underlined) was calculated for all three possible changes of cytosine (or guanine) as described in the Online Methods. ***Bonferroni-corrected q value < 0.0001, as determined by a one-tailed Fisher's exact test comparing the ratio of the number of cytosine mutations at TCW motifs and the number of cytosine mutations not in the sequence TCW (R is A or G, Y is T or C) to the analogous ratio for all cytosines within a sample fraction of the genome. Bottom, the numbers and fractions (above appropriate sections of the bars) of three different base substitutions of cytosine (or guanine). a n a ly s i s Spearman's r = 0.3088, Bonferroni-corrected q < 0.001 for APOBEC3B and APOBEC3A, respectively). Extending this analysis to all 2,048 tumors with available RNA-seq data across cancer types, expression of APOBEC3B again most strongly correlated with the number of TCW-to-TTW and TCW-to-TGW mutations per exome ( Fig. 3a and Supplementary Table 4; Spearman's r = 0.2953, Bonferroni-corrected q < 0.001), with APOBEC1, APOBEC3A, APOBEC3F and APOBEC3G levels also associated, but to lesser extents (Supplementary Fig. 11b ). Within individual cancer types, only APOBEC3A in breast cancer and APOBEC3B in breast cancer and lung adenocarcinomas showed a positive correlation between their expression and APOBEC-mediated mutagenesis (Supplementary Fig. 11b ). However, in bladder and lung squamous cell cancers-the remaining 2 cancer types with available RNA-seq data and high APOBEC-mediated mutagenesismedian APOBEC3B expression was elevated by ~3-fold compared to the median of APOBEC3B expression in all samples (Bonferronicorrected Mann-Whitney q < 0.001) (Fig. 3b) . Thus, the APOBEC3B enzyme is probably the major candidate inducing the APOBEC mutation pattern across cancer types.
HER2E breast cancers are enriched for APOBEC mutagenesis
Several cancer types showed high levels of the APOBEC mutation pattern as well as a wide variation among individual samples, which could reflect different biological pathways leading to carcinogenesis. The greatest range of variation was observed in breast cancer, which is often divided into subtypes on the basis of differences in biomedical characteristics (see ref. 25 and references therein). To determine whether the APOBEC mutagenesis pattern is associated with specific breast cancer subtypes, we divided the samples on the basis of their PAM50 classification as presented in ref. 25 . The PAM50 algorithm uses the mRNA levels of 50 differentially expressed genes to classify breast cancers into specific subtypes 26 . Four subtypes-luminal A (Lum A), luminal B (Lum B), basal-like and HER2 enriched (HER2E)-were well represented in our data set. Each subtype contained samples with a prominent APOBEC mutation pattern and a correspondingly large number of APOBEC signature mutations. However, such samples were unevenly distributed among the subtypes, occurring much more frequently in the HER2-enriched class (Fig. 4 and Supplementary Fig. 12) .
Unlike in breast cancer as a whole (Fig. 3a) , no correlation between the number of APOBEC signature mutations and APOBEC mRNA levels was observed in the HER2-enriched subtype ( Supplementary  Fig. 13a ). This finding could result from consistently high APOBEC3B expression in HER2-enriched samples (~3-fold greater than the median expression across all cancer types), which reduces the power of correlation analysis (Supplementary Fig. 13b) . Notably, basal-like and luminal B cancers also had median APOBEC3B expression levels comparable to that of HER2-enriched cancers but showed significantly less APOBEC mutagenesis, suggesting that additional factors are likely as important as APOBEC expression.
The HER2-enriched subtype is reportedly associated not only with the amplification of the ERBB2 gene locus but also with a high level of copy number variation (CNV) across the genome 25 . This feature, as well as frequent colocalization of APOBEC signature mutations with chromosome rearrangements, suggested that a direct connection might exist between enrichment with the APOBEC mutagenesis signature and the number of segmental CNVs (CNVs originating from breakage). As shown in cell culture experiments 27 , increased APOBEC-induced deamination can lead to higher levels of breakage, which in turn could result in greater numbers of CNVs. Alternatively, increased breakage could provide more ssDNA substrate for APOBEC deamination. However, comparison of the number of segmental CNV breakpoints with the fold enrichment of APOBEC signature mutations in 449 breast cancer samples did not show any correlation (Supplementary Fig. 14) . Although the underlying reason for the enrichment of the APOBEC mutagenesis pattern in the HER2-enriched subtype remains unclear, the association of this mutagenesis with a specific breast cancer subtype suggests that physiological aspects of this subtype are probably relevant. npg a n a ly s i s
The APOBEC mutagenesis pattern includes cancer driver genes An APOBEC-mediated mutagenesis pattern present in a sample or group of samples indicates that the level of this mutagenesis is significantly higher than expected if all base substitutions in cytosine (or guanine) bases have occurred randomly. However, because of the sequence specificity of APOBEC-catalyzed deamination and its tight association with ssDNA, the fraction of the genome where carcinogenic mutations can occur may escape the bulk of APOBEC-mediated mutagenesis. We therefore examined the overlap of APOBEC signature mutations with mutations that are potentially cancer drivers. Three approaches were used to identify driver mutations. First, a stringent list of probable cancer driver mutations was assembled using the online software package CRAVAT 28, 29 . On the basis of multiple parameters, including the occurrence of a mutation in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 30 , this software calculated a probability that a given missense mutation drives cancer. Mutations having false discovery rate (FDR)-corrected q values of 0.05 or less were selected as likely drivers. We subsequently employed two additional 'less stringent' criteria to identify potentially carcinogenic mutations, selecting for (i) mutations that were present in the COSMIC database (as indicated by CRAVAT) and (ii) mutations that affected a subset of genes from the Cancer Gene Censusgenes in which missense or nonsense mutations are considered causative in cancer 31 . Both of these less stringent definitions of driver mutations extended the spectrum of changes beyond missense mutations to include nonsense and synonymous mutations as potentially carcinogenic alterations 31, 32 . Using any of these three criteria, APOBEC signature mutations occurred at a higher frequency among carcinogenic mutations in the group of samples with high APOBEC presence compared to samples in which the APOBEC mutation pattern was not detected npg a n a ly s i s (Fig. 5) . This implies that APOBEC signature mutations themselves can contribute to carcinogenesis in samples with a strong APOBEC mutation pattern. Further supporting this carcinogenic potential, many of the APOBEC signature mutations that are also driver mutations in CRAVAT occurred in genes that are highly mutated in the COSMIC database and are present in the Cancer Gene Census (Supplementary Table 5 ).
DISCUSSION
Determining the mutagenic factors that underlie the mix of mutations in tumors is important for a general understanding of carcinogenesis. However, this analysis is daunting, as it often requires the testing of numerous poorly defined hypotheses. Here we have developed a single detailed hypothesis-that APOBEC cytidine deaminases are a significant source of mutagenesis in human cancer genomes. This hypothesis is based on knowledge of the sequence-and single-strand specificity of APOBEC enzymes, their capacity to generate strand-coordinated mutation clusters in model systems and the extensive correlation between experimentally determined APOBEC mutagenesis patterns and the patterns of mutations in strand-coordinated clusters found in cancers. Although we cannot formally exclude the possibility that another mutagenic factor might closely mimic both the motif and mutagenic specificities of the APOBEC mutation pattern, there is yet no indication that such a factor exists. Furthermore, our observed correlation between the APOBEC mutagenesis pattern and APOBEC expression in cancer samples provides strong support for our hypothesis. Additional support could be sought by analyzing correlations with the germline genotypes of patients, as soon as such information would be available. Our TCGA-based analysis indicates a widespread APOBEC mutagenesis pattern and suggests that this pattern is associated with biological mechanisms underlying carcinogenesis. With our approach, we establish a resource for identifying this pattern in the rapidly growing TCGA database as well as in other databases of genome-or exomewide mutations in humans. In addition, the predominance of APOBEC signature mutations across tumors of multiple cancer types underscores the importance of validating the specific APOBEC proteins responsible for mutagenesis and evaluating the presence of this mutagenesis in other types and subtypes of cancers, the stage(s) of cancer development that are most prone to APOBEC mutagenesis and the relative impact of this mutagenesis on genome changes that lead to cancer.
Multiple mechanisms could facilitate APOBEC-mediated mutagenesis. Environmental and physiological factors might trigger and/ or support mutagenesis by (i) affecting the cellular abundance or activity of APOBEC proteins, (ii) altering access to nuclear DNA and (iii) increasing the amount and/or persistence of ssDNA substrates for APOBEC-mediated cytidine deamination. Our study and previous analyses suggest that the level of APOBEC3B transcription affects APOBEC-mediated mutagenesis. How higher APOBEC3B transcript levels are established remains unclear. Among the factors that could increase the amount of APOBEC protein(s) is the presence of the viral and retrotransposable elements that these enzymes restrict 6, 33 . Such factors can stimulate APOBEC expression through a complex network of innate immunity signaling, involving components such as Toll-like receptors, interferons, interleukins and even the 'usual suspect' in carcinogenesis, the p53 protein [34] [35] [36] [37] . Infection with several viruses 38 as well as retrotransposition 39 are associated with carcinogenesis; however, the mechanisms of this association are far from clear. A potential relationship between APOBEC-mediated mutagenesis and viral infection is appealing, as cervical and head and neck cancers, which are highly associated with human papillomavirus (HPV) infection, showed strong enrichment of APOBEC-mediated mutagenesis.
Despite a positive correlation between APOBEC3B expression and APOBEC-mediated mutagenesis, the extent of the association is relatively small (Spearman's r = 0.30). Thus, other factors probably contribute more prominently to APOBEC-mediated mutagenesis. Factors that could increase the abundance and persistence of ssDNA include DNA-damaging agents 40, 41 as well as defects in DNA transactions that impede break repair 42, 43 and replication integrity 44, 45 . Our work in yeast demonstrated that proliferation in the presence of an alkylation agent leads to the formation of ssDNA at DSB sites and dysfunctional forks and subsequently results in mutation clusters 13 . Notably, a high level of APOBEC-mediated deamination may in itself lead to DNA breakage 27 , which could generate a ssDNA substrate for APOBECmediated hypermutation. It is generally acknowledged that carcinogenesis requires the accumulation of multiple genetic changes 46 . As discussed in ref. 13 , simultaneous mutations in scattered stretches of ssDNA formed at DSBs, replication forks and other cell contexts would be excellent substrates for APOBEC-mediated mutagenesis, which in turn might produce multiple changes without excessive genome-wide mutation and provide a means to accumulate multiple carcinogenic mutations in a single or a few generations.
URLs. TCGA data portal, https://tcga-data.nci.nih.gov/tcga/ tcgaDownload.jsp; database of Genotypes and Phenotypes (dbGaP), http://www.ncbi.nlm.nih.gov/gap; 21 breast cancer genomes, ftp:// ftp.sanger.ac.uk/pub/cancer/Nik-ZainalEtAl; 9 colorectal adenocarcinoma genomes, http://www.broadinstitute.org/~lawrence/crc/ CRC9.genomic.v3.maf; CRAVAT, http://www.cravat.us/; COSMIC database, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/; Cancer Gene Census, http://cancer.sanger.ac.uk/cancergenome/ projects/census/.
METHODS
Methods and any associated references are available in the online version of the paper. The fraction of potential cancer-driving mutations that have an APOBEC signature was determined for samples with high (q value for the enrichment of the APOBEC mutation pattern ≤ 0.05; Fig. 2 ) and low (q value > 0.05) presence of an exome-wide APOBEC mutation pattern. Mutations were designated as potential cancer drivers by one of three criteria: (i) Benjamini-Hochberg-corrected q value < 0.05 after CRAVAT analysis, (ii) listing within the COSMIC database and (iii) effect on a subset of genes in the Cancer Gene Census, whose alteration by missense or nonsense mutations can contribute to cancer. ***P < 0.0001 in a two-sided χ 2 test comparing the number of APOBEC and non-APOBEC signature mutations in potential cancer drivers in samples with high and low presence of the APOBEC mutation pattern for a given criterion defining a driver. Corresponding analysis for non-driver mutations is provided for comparison. The specific mutated genes are presented in supplementary Table 5. npg
